



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 642 798 A2

(12)

EUROPEAN PATENT APPLICATION

23

(21) Application number: 93309720.6

(51) Int. Cl. 5: **A61K 47/48**

(22) Date of filing: 03.12.93

(30) Priority: 08.09.93 US 118055
22.10.93 US 142598
15.11.93 US 152506
22.11.93 EP 93309288

(43) Date of publication of application:
15.03.95 Bulletin 95/11

(94) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL
PT SE

(71) Applicant: **LA JOLLA PHARMACEUTICAL
COMPANY**
6455 Nancy Ridge Drive, Suite 300
San Diego, California 92121 (CA)

(72) Inventor: **Coutts, Stephen**
6151 Rancho Diegueno Road
Rancho Santa Fe, CA 92067 (US)
Inventor: **Jones, David S.**
11265 Florindo Road
San Diego, CA 92127 (US)
Inventor: **Livingston, Douglas Alan**
5260 Fiore Terrace, No.115
San Diego, CA 92122 (US)
Inventor: **Yu, Lin**
8933 Lombard Place, Apt. 228
San Diego, CA 92122 (US)

(74) Representative: **Goldin, Douglas Michael et al**
J.A. KEMP & CO.
14, South Square
Gray's Inn
London WC1R 5LX (GB)

(54) **Chemically-defined non-polymeric valency platform molecules and conjugates thereof.**

(57) **Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.**

EP 0 642 798 A2